PMID- 27627120
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20181113
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Print)
IS  - 0104-1169 (Linking)
VI  - 24
IP  - 0
DP  - 2016 Sep 9
TI  - Tuberculosis control in people living with HIV/AIDS.
PG  - e2798
LID - S0104-11692016000100410 [pii]
LID - 10.1590/1518-8345.1187.2798 [doi]
LID - e2798
AB  - OBJECTIVE: to analyze the offering of health actions and services for the control of 
      tuberculosis for people living with HIV/AIDS being followed up in the Specialized 
      Care Services for HIV/AIDS in Ribeirão Preto, SP, Brazil. METHOD: quantitative, 
      exploratory survey study. Participated 253 people living with HIV/AIDS followed up 
      by this service, considering as inclusion criteria: individuals older than 18 years 
      living in the city and not inmates. Data collection was conducted from January 2012 
      to May 2013 through interviews with the support of a specific instrument. Data were 
      analyzed using indicators and a composite index. RESULTS: the offering of services 
      for the control of tuberculosis in people living with HIV/AIDS by municipal services 
      was considered as intermediate, reinforcing the need for better planning for 
      comprehensive assistance, coordination of professionals in teams and among the 
      services network, in addition to professional training and continuing education. 
      CONCLUSION: it is necessary to implement strategies that promote shared actions 
      between TB and HIV / AIDS programs and between different services in order to 
      strengthen the local care network, aimed at producing an individualized care, 
      comprehensive and responsive. OBJETIVO: analisar a oferta das ações e serviços de 
      saúde para o controle da tuberculose nas pessoas vivendo com HIV/aids em seguimento 
      pelos Serviços de Atenção Especializada ao HIV/aids de Ribeirão Preto, SP, Brasil. 
      MÉTODO: estudo quantitativo, exploratório, do tipo inquérito. Participaram 253 
      pessoas vivendo com HIV/aids em seguimento nos serviços, considerando os critérios 
      de inclusão: indivíduos maiores de 18 anos, residentes no município e não 
      pertencentes ao sistema prisional. A coleta de dados foi realizada no período de 
      janeiro/2012 a maio/2013, por meio de entrevistas com apoio de um instrumento 
      específico. Os dados foram analisados mediante indicadores e índice composto. 
      RESULTADOS: a oferta de ações e serviços para o controle da tuberculose nas pessoas 
      vivendo com HIV/aids pelos serviços do município foi considerada regular, reforçando 
      a necessidade de melhor planejamento da assistência de forma integral, articulação 
      dos profissionais nas equipes e entre os serviços da rede, além da formação 
      profissional e educação permanente. CONCLUSÃO: faz-se necessário a implementação de 
      estratégias que favoreçam ações compartilhadas entre os programas de tuberculose e 
      HIV/aids e entre os diferentes serviços, com o intuito de fortalecer a rede local de 
      atenção objetivando a produção de um cuidado singular, integral e resolutivo. 
      OBJETIVO: analizar la oferta de acciones y servicios de salud para el control de la 
      tuberculosis en las personas viviendo con VIH-SIDA acompañadas por los Servicios de 
      Atención Especializada al VIH-SIDA de Ribeirao Preto, SP, Brasil. MÉTODO: estudio 
      cuantitativo, exploratorio, de tipo encuesta. Participaron 253 personas viviendo con 
      VIH-SIDA seguidas por estos servicios, considerando como criterios de inclusión: 
      individuos mayores de 18 años, residentes en el municipio y no ser del sistema de 
      prisiones. La recolección de datos fue realizada en el periodo de enero de 2012 a 
      mayo de 2013, por medio de entrevistas guiadas por un instrumento especifico. Los 
      datos fueron analizados mediante indicadores y un índice compuesto. RESULTADOS: la 
      oferta de acciones y servicios para el control de la tuberculosis en personas 
      viviendo con VIH-SIDA fue considerada intermedia, reforzando la necesidad de mejorar 
      la planificación de la asistencia en forma integral, la articulación de los 
      profesionales en los equipos y entre los servicios de la red, además de la formación 
      profesional y la educación permanente. CONCLUSIÓN: se hace necesaria la 
      implementación de estrategias que favorezcan las acciones compartidas entre los 
      programas de tuberculosis y VIH-SIDA y entre los diferentes servicios, con el fin de 
      fortalecer la red local de atención para producir un cuidado personalizado, integral 
      y resolutivo.
FAU - Magnabosco, Gabriela Tavares
AU  - Magnabosco GT
AD  - PhD, Post-doctoral fellow, Escola de Enfermagem de Ribeirão Preto, Universidade de 
      São Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
FAU - Lopes, Lívia Maria
AU  - Lopes LM
AD  - MSc, Doctoral student, Escola de Enfermagem de Ribeirão Preto, Universidade de São 
      Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
FAU - Andrade, Rubia Laine de Paula
AU  - Andrade RL
AD  - PhD, RN, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, PAHO/WHO 
      Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
FAU - Brunello, Maria Eugênia Firmino
AU  - Brunello ME
AD  - PhD, Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, 
      PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, 
      Brazil.
FAU - Monroe, Aline Aparecida
AU  - Monroe AA
AD  - PhD, Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, 
      PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, 
      Brazil.
FAU - Villa, Tereza Cristina Scatena
AU  - Villa TC
AD  - PhD, Full Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São 
      Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
LA  - eng
LA  - por
LA  - spa
PT  - Journal Article
DEP - 20160909
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Acquired Immunodeficiency Syndrome/complications
MH  - Adult
MH  - Brazil
MH  - HIV Infections/*complications
MH  - Humans
MH  - Tuberculosis/*complications/*prevention & control
PMC - PMC5048724
EDAT- 2016/09/15 06:00
MHDA- 2017/11/01 06:00
CRDT- 2016/09/15 06:00
PHST- 2015/07/30 00:00 [received]
PHST- 2016/03/15 00:00 [accepted]
PHST- 2016/09/15 06:00 [entrez]
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S0104-11692016000100410 [pii]
AID - 10.1590/1518-8345.1187.2798 [doi]
PST - epublish
SO  - Rev Lat Am Enfermagem. 2016 Sep 9;24(0):e2798. doi: 10.1590/1518-8345.1187.2798.

PMID- 31093179
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200225
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Print)
IS  - 1020-4989 (Linking)
VI  - 42
DP  - 2018
TI  - [HIV/Aids management at the primary care level in Brazil: a challenge for the 
      Unified Health System?Cuidados de pacientes VIH / SIDA y atención primaria en 
      Brasil: desafíos para la atención en el Sistema Único de Salud?].
PG  - e151
LID - 10.26633/RPSP.2018.151 [doi]
LID - e151
AB  - In Brazil, the Unified Health System (SUS) entails the establishment of hierarchical 
      and regionalized networks coordinated from the primary health care (PHC) level, 
      which is also the entry point into the system. Recently, as a result of new 
      guidelines and experiences in Brazil, PCH has been assigned a more substantial role 
      in the care and management of people living with HIV/Aids, tasks traditionally 
      performed at specialized clinics. The present article contextualizes and 
      problematizes this recent process of decentralized care to people living the 
      HIV/Aids in the context of the SUS. Since 2011, new diagnostic technologies (such as 
      rapid testing)) have been become available at PHC units in Brazil, expanding access 
      to testing and promoting an increase in the number of HIV diagnoses performed at the 
      PHC level. Since 2013, new guidelines and recommendations have also supported the 
      management of people with HIV/Aids in PHC units. The present article examines the 
      relationship between PHC and specialized care, issues of access, stigma, and 
      confidentiality within PHC, and the mode of organization and functioning of family 
      health teams, especially the formal link between residents in catchment areas and 
      health teams and workers. In conclusion, many challenges - moral, ethical, 
      technical, organizational, and political - have to be faced in order to increase 
      access and quality of care in the context of PHC for people living with HIV/Aids in 
      Brazil.
FAU - Melo, Eduardo Alves
AU  - Melo EA
AD  - Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública (ENSP), Rio de Janeiro (RJ), 
      Brasil.
FAU - Maksud, Ivia
AU  - Maksud I
AD  - Fundação Oswaldo Cruz, Instituto Fernandes Figueira, Rio de Janeiro (RJ), Brasil.
FAU - Agostini, Rafael
AU  - Agostini R
AD  - Fundação Oswaldo Cruz, Instituto Fernandes Figueira, Rio de Janeiro (RJ), Brasil.
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Cuidado, HIV/Aids e atenção primária no Brasil: desafio para a atenção no Sistema 
      Único de Saúde?
DEP - 20181127
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC6386111
OAB - Publisher: Abstract available from the publisher.
OABL- por
OTO - NOTNLM
OT  - Brazil
OT  - Primary health care
OT  - acquired immunodeficiency syndrome
OT  - comprehensive health care
COIS- Conflitos de interesse. Nada declarado pelos autores.
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:01
CRDT- 2019/05/17 06:00
PHST- 2017/12/24 00:00 [received]
PHST- 2018/08/13 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:01 [medline]
AID - RPSP.2018.151 [pii]
AID - 10.26633/RPSP.2018.151 [doi]
PST - epublish
SO  - Rev Panam Salud Publica. 2018 Nov 27;42:e151. doi: 10.26633/RPSP.2018.151. 
      eCollection 2018.

PMID- 34152663
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 24
IP  - 6
DP  - 2021 Jun
TI  - Trends in demographic and clinical characteristics and initiation of antiretroviral 
      therapy among adult patients enrolling in HIV care in the Central Africa 
      International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018.
PG  - e25672
LID - 10.1002/jia2.25672 [doi]
LID - e25672
AB  - INTRODUCTION: The Central Africa International epidemiology Database to Evaluate 
      AIDS (CA-IeDEA) is an open observational cohort study investigating impact, 
      progression and long-term outcomes of HIV/AIDS among people living with HIV (PLWH) 
      in Burundi, Cameroon, Democratic Republic of Congo (DRC), Republic of Congo (ROC) 
      and Rwanda. We describe trends in demographic, clinical and immunological 
      characteristics as well as antiretroviral therapy (ART) use of patients 
      aged > 15 years entering into HIV care in the participating CA-IeDEA site. METHODS: 
      Information on sociodemographic characteristics, height, weight, body mass index 
      (BMI), CD4 cell count, WHO staging and ART status at entry into care from 2004 
      through 2018 were extracted from clinic records of patients aged > 15 years 
      enrolling in HIV care at participating clinics in Burundi, Cameroon, DRC, ROC and 
      Rwanda. We assessed trends in patient characteristics at enrolment in HIV care 
      including ART initiation within the first 30 days after enrolment in care and 
      calculated proportions, means and medians (interquartile ranges) for the main 
      variables of interest. RESULTS: Among 69,176 patients in the CA-IeDEA cohort, 39% 
      were from Rwanda, 24% from ROC, 18% from Cameroon, 14% from Burundi and 5% from DRC. 
      More women (66%) than men enrolled in care and subsequently initiated ART. Women 
      were also younger than men (32 vs. 38 years, P < 0.001) at enrolment and at ART 
      initiation. Trends over time show increases in median CD4 cell count at enrolment 
      from 190 cells/µL in 2004 to 334 cells/µL in 2018 at enrolment. Among those with 
      complete data on CD4 counts (60%), women had a higher median CD4 cell count at care 
      entry than men (229 vs. 249 cells/µL, P < 0.001). Trends in the proportion of 
      patients using ART within 30 days of enrolment at the participating site show an 
      increase from 16% in 2004 to 75% in 2018. CONCLUSIONS: Trends from 2004 to 2018 in 
      the characteristics of patients participating in the CA-IeDEA cohort highlight 
      improvements at entry into care and subsequent ART initiation including after the 
      implementation of Treat All guidelines in the participating sites.
CI  - © 2021 The Authors. Journal of the International AIDS Society published by John 
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Adedimeji, Adebola A
AU  - Adedimeji AA
AUID- ORCID: 0000-0002-8012-9124
AD  - Department of Epidemiology and Population Health, Albert Einstein College of 
      Medicine/Montefiore Medical Center, Bronx, NY, USA.
FAU - Hoover, Donald R
AU  - Hoover DR
AD  - Department of Statistics, Rutgers University, Piscataway, NJ, USA.
FAU - Shi, Qiuhu
AU  - Shi Q
AD  - Department of Public Health, School of Health Sciences and Practice, New York 
      Medical College, Valhalla, NY, USA.
FAU - Kim, Hae-Young
AU  - Kim HY
AD  - Department of Public Health, School of Health Sciences and Practice, New York 
      Medical College, Valhalla, NY, USA.
FAU - Brazier, Ellen
AU  - Brazier E
AUID- ORCID: 0000-0002-8514-1958
AD  - School of Public Health, City University of New York, New York, NY, USA.
FAU - Ross, Jonathan
AU  - Ross J
AUID- ORCID: 0000-0001-6126-3048
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Murenzi, Gad
AU  - Murenzi G
AD  - Division of Clinical Education, Rwanda Military Hospital, Kanombe, Kigali, Rwanda.
FAU - Twizere, Christella
AU  - Twizere C
AUID- ORCID: 0000-0003-1102-5564
AD  - Centre National de Reference en Matière de VIH/SIDA, Bujumbura, Burundi.
FAU - Lelo, Patricia
AU  - Lelo P
AD  - Pediatric Hospital Kalembe Lembe, Kinshasa, Democratic Republic of Congo.
FAU - Nsonde, Dominique
AU  - Nsonde D
AD  - CTA Brazzaville, Brazzaville, Republic of Congo.
FAU - Ajeh, Rogers
AU  - Ajeh R
AD  - Clinical Research Education, Networking and Consultancy, Yaounde, Cameroon.
FAU - Dzudie, Anastase
AU  - Dzudie A
AD  - Clinical Research Education, Networking and Consultancy, Yaounde, Cameroon.
FAU - Nash, Denis
AU  - Nash D
AD  - School of Public Health, City University of New York, New York, NY, USA.
FAU - Yotebieng, Marcel
AU  - Yotebieng M
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Anastos, Kathryn
AU  - Anastos K
AD  - Department of Epidemiology and Population Health, Albert Einstein College of 
      Medicine/Montefiore Medical Center, Bronx, NY, USA.
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
CN  - Central Africa IeDEA Consortium
LA  - eng
GR  - U01 AI096299/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome/drug therapy
MH  - Adult
MH  - Africa, Central/epidemiology
MH  - Aged
MH  - *Anti-HIV Agents/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Demography
MH  - Female
MH  - *HIV Infections/drug therapy/epidemiology
MH  - Humans
MH  - Male
PMC - PMC8216247
OTO - NOTNLM
OT  - *ARV
OT  - *Africa
OT  - *HIV care continuum
OT  - *HIV epidemiology
OT  - *cohort studies
OT  - *low- and middle-income countries
FIR - Pélagie, Nimbona
IR  - Pélagie N
FIR - Gateretse, Patrick
IR  - Gateretse P
FIR - Munezero, Jeanine
IR  - Munezero J
FIR - Nitereka, Valentin
IR  - Nitereka V
FIR - Niyongabo, Théodore
IR  - Niyongabo T
FIR - Twizere, Christelle
IR  - Twizere C
FIR - Bukuru, Hélène
IR  - Bukuru H
FIR - Nahimana, Thierry
IR  - Nahimana T
FIR - Baransaka, Elysée
IR  - Baransaka E
FIR - Barasukana, Patrice
IR  - Barasukana P
FIR - Kabanda, Eugene
IR  - Kabanda E
FIR - Manirakiza, Martin
IR  - Manirakiza M
FIR - Ndikumwenayo, François
IR  - Ndikumwenayo F
FIR - Biziragusenyuka, Jérémie
IR  - Biziragusenyuka J
FIR - Munezero, Ange Marie Michelline
IR  - Munezero AMM
FIR - Mbuh, Tabeyang
IR  - Mbuh T
FIR - Njie, Kinge Thompson
IR  - Njie KT
FIR - Tchassem, Edmond
IR  - Tchassem E
FIR - Tsi, Kien-Atsu
IR  - Tsi KA
FIR - Benwi, Mark
IR  - Benwi M
FIR - Ngamani, Marc Lionel
IR  - Ngamani ML
FIR - Nkome, Victorine
IR  - Nkome V
FIR - Sandjong, Falone
IR  - Sandjong F
FIR - Mbuh, Akindeh
IR  - Mbuh A
FIR - Amadou, Djenabou
IR  - Amadou D
FIR - Balkissou, Amadou Dodo
IR  - Balkissou AD
FIR - Ngassam, Eric
IR  - Ngassam E
FIR - Yone, Eric Walter Pefura
IR  - Yone EWP
FIR - Ewanoge, Alice Ndelle
IR  - Ewanoge AN
FIR - Fuhngwa, Norbert
IR  - Fuhngwa N
FIR - Kendowo, Ernestine
IR  - Kendowo E
FIR - Moki, Chris
IR  - Moki C
FIR - Nforniwe, Denis Nsame
IR  - Nforniwe DN
FIR - Akele, Catherine
IR  - Akele C
FIR - Kitetele, Faustin
IR  - Kitetele F
FIR - Tabala, Martine
IR  - Tabala M
FIR - Okitolonda, Emile Wemakoy
IR  - Okitolonda EW
FIR - Ekembe, Cherubin
IR  - Ekembe C
FIR - Diafouka, Merlin
IR  - Diafouka M
FIR - Ekat, Martin Herbas
IR  - Ekat MH
FIR - Mafou, Adolphe
IR  - Mafou A
FIR - Ayinkamiye, Nicole
IR  - Ayinkamiye N
FIR - Igirimbabazi, Jules
IR  - Igirimbabazi J
FIR - Ndamijimana, Emmanuel
IR  - Ndamijimana E
FIR - Habarurema, Emmanuel
IR  - Habarurema E
FIR - Nyiraneza, Marie Luise
IR  - Nyiraneza ML
FIR - Mukamusana, Dorothee
IR  - Mukamusana D
FIR - Tuyisenge, Liliane
IR  - Tuyisenge L
FIR - Kankindi, Catherine
IR  - Kankindi C
FIR - Shyaka, Christian
IR  - Shyaka C
FIR - Ingabire, Marie Grace
IR  - Ingabire MG
FIR - Uwakijijwe, Bonheur
IR  - Uwakijijwe B
FIR - Ndumuhire, Jules
IR  - Ndumuhire J
FIR - Nyirabahutu, Marie Goretti
IR  - Nyirabahutu MG
FIR - Ndoli, Yvette
IR  - Ndoli Y
FIR - Uwamahoro, Oliver
IR  - Uwamahoro O
FIR - Muhayimpundu, Ribakare
IR  - Muhayimpundu R
FIR - Nsanzimana, Sabin
IR  - Nsanzimana S
FIR - Remera, Eric
IR  - Remera E
FIR - Umumararungu, Esperance
IR  - Umumararungu E
FIR - Busingye, Lydia
IR  - Busingye L
FIR - Butera, Alex M
IR  - Butera AM
FIR - Gasana, Josephine
IR  - Gasana J
FIR - Habiryayo, Thierry
IR  - Habiryayo T
FIR - Ingabire, Charles
IR  - Ingabire C
FIR - Kabahizi, Jules
IR  - Kabahizi J
FIR - Kagimbana, Jean Chrysostome
IR  - Kagimbana JC
FIR - Kanyabwisha, Faustin
IR  - Kanyabwisha F
FIR - Kubwimana, Gallican
IR  - Kubwimana G
FIR - Muhoza, Benjamin
IR  - Muhoza B
FIR - Munyaneza, Athanase
IR  - Munyaneza A
FIR - Musabyimana, Francoise
IR  - Musabyimana F
FIR - Mwiza, Francine
IR  - Mwiza F
FIR - Rwibasira, Gallican Nshogoza
IR  - Rwibasira GN
FIR - Sinayobye, Jean d'Amour
IR  - Sinayobye JD
FIR - Tuyisenge, Patrick
IR  - Tuyisenge P
FIR - Benekigeri, Chantal
IR  - Benekigeri C
FIR - Musaninyange, Jacqueline
IR  - Musaninyange J
FIR - Adedimeji, Adebola
IR  - Adedimeji A
FIR - Dilorenzo, Madeline
IR  - Dilorenzo M
FIR - Murchison, Lynn
IR  - Murchison L
FIR - Addison, Diane
IR  - Addison D
FIR - Jones, Heidi
IR  - Jones H
FIR - Kelvin, Elizabeth
IR  - Kelvin E
FIR - Kulkarni, Sarah
IR  - Kulkarni S
FIR - Romo, Matthew
IR  - Romo M
FIR - Tymejczyk, Olga
IR  - Tymejczyk O
FIR - Elul, Batya
IR  - Elul B
FIR - Cai, Xiatao
IR  - Cai X
FIR - Dong, Allan
IR  - Dong A
FIR - Hoover, Don
IR  - Hoover D
FIR - Li, Chunshan
IR  - Li C
FIR - Shi, Qiuhu
IR  - Shi Q
FIR - Agler, Robert
IR  - Agler R
FIR - Lancaster, Kathryn
IR  - Lancaster K
FIR - Kuniholm, Mark
IR  - Kuniholm M
FIR - Edmonds, Andrew
IR  - Edmonds A
FIR - Parcesepe, Angela
IR  - Parcesepe A
FIR - Edwards, Jess
IR  - Edwards J
FIR - Keiser, Olivia
IR  - Keiser O
FIR - Duda, Stephany
IR  - Duda S
FIR - Kimmel, April
IR  - Kimmel A
EDAT- 2021/06/22 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/06/21 12:33
PHST- 2020/11/17 00:00 [revised]
PHST- 2020/06/25 00:00 [received]
PHST- 2021/01/27 00:00 [accepted]
PHST- 2021/06/21 12:33 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - JIA225672 [pii]
AID - 10.1002/jia2.25672 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2021 Jun;24(6):e25672. doi: 10.1002/jia2.25672.

PMID- 29165512
OWN - NLM
STAT- MEDLINE
DCOM- 20180131
LR  - 20180131
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 34
IP  - 4
DP  - 2017 Aug
TI  - [Antiretroviral treatment adherence for HIV/AIDS in women: a sociocultural 
      perspective].
PG  - 352-358
LID - S0716-10182017000400352 [pii]
LID - 10.4067/s0716-10182017000400352 [doi]
AB  - BACKGROUND: Adequate adherence to HAART has a high impact on survival of AIDA 
      patients. There is little consensus on the causes of low adherence to treatment in 
      women, who are in a situation of inequality in terms of prevention and related care. 
      OBJECTIVES: To explore and describe the socio-cultural aspects related to the 
      adherence of women to antiretroviral treatment for HIV / AIDS. MATERIAL AND METHODS: 
      Qualitative, exploratory-descriptive study. The study population was focused on 
      Chilean women, who are 18 years of age or older, living with HIV/AIDS. The sample 
      size was defined by information saturation. In-depth interviews were conducted with 
      16 women contacted in seven public care centers for people living with HIV (PLHIV) 
      in 4 regions of the country, and it was take into account the saturation of the 
      information. RESULTS: There are several sociocultural factors that determine the 
      level of adherence that women adopt in relation to HAART. The most relevant ones are 
      the vital satisfaction, the imaginary about HIV, the availability of their networks 
      in front of diagnosis and the availability of information are fundamental. 
      DISCUSSION: It is necessary to enter into specific interventions considering the 
      sociocultural aspects and satisfying the psychosocial needs of women. It is 
      imperative that public policies and health teams consider these aspects to improve 
      adherence to HAART.
FAU - Belmar, Julieta
AU  - Belmar J
AD  - Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Chile.
FAU - Stuardo, Valeria
AU  - Stuardo V
AD  - Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Chile.
LA  - spa
PT  - Journal Article
TT  - Adherencia al tratamiento anti-retroviral para el VIH/SIDA en mujeres: una mirada 
      socio-cultural.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de 
      Infectologia
JID - 9305754
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - Chile
MH  - *Cultural Characteristics
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Medication Adherence/psychology/*statistics & numerical data
MH  - Qualitative Research
MH  - Sex Factors
MH  - Socioeconomic Factors
EDAT- 2017/11/23 06:00
MHDA- 2018/02/01 06:00
CRDT- 2017/11/23 06:00
PHST- 2016/12/05 00:00 [received]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/11/23 06:00 [entrez]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2018/02/01 06:00 [medline]
AID - S0716-10182017000400352 [pii]
AID - 10.4067/s0716-10182017000400352 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2017 Aug;34(4):352-358. doi: 10.4067/s0716-10182017000400352.

PMID- 26821952
OWN - NLM
STAT- MEDLINE
DCOM- 20161104
LR  - 20181113
IS  - 1813-4424 (Electronic)
IS  - 1729-0376 (Print)
IS  - 1729-0376 (Linking)
VI  - 13
IP  - 1
DP  - 2016
TI  - Weak signal detection: A discrete window of opportunity for achieving 'Vision 
      90:90:90'?
PG  - 17-34
LID - 10.1080/17290376.2015.1123642 [doi]
AB  - INTRODUCTION: UNAIDS' Vision 90:90:90 is a call to 'end AIDS'. Developing predictive 
      foresight of the unpredictable changes that this journey will entail could 
      contribute to the ambition of 'ending AIDS'. There are few opportunities for 
      managing unpredictable changes. We introduce 'weak signal detection' as a potential 
      opportunity to fill this void. METHOD: Combining futures and complexity theory, we 
      reflect on two pilot case studies that involved the Archetype Extraction technique 
      and the SenseMaker(®) Collector(™) tool. RESULTS: Both the piloted techniques have 
      the potentials to surface weak signals--but there is room for improvement. 
      DISCUSSION: A management response to a complex weak signal requires pattern 
      management, rather than an exclusive focus on behaviour management. CONCLUSION: Weak 
      signal detection is a window of opportunity to improve resilience to unpredictable 
      changes in the HIV/AIDS landscape that can both reduce the risk that emerges from 
      the changes and increase the visibility of opportunities to exploit the 
      unpredictable changes that could contribute to 'ending AIDS'.
FAU - Burman, Christopher J
AU  - Burman CJ
AD  - a PhD, is affiliated to Rural Development and Innovation Hub , University of Limpopo 
      , Turfloop Campus, Polokwane , South Africa.
FAU - Aphane, Marota
AU  - Aphane M
AD  - b Masters in Development, is affiliated to Rural Development and Innovation Hub , 
      University of Limpopo , Turfloop Campus, Polokwane , South Africa.
FAU - Delobelle, Peter
AU  - Delobelle P
AD  - c MD, PhD is affiliated to School of Public Health , University of the Western Cape 
      , Robert Sobukwe Road, Belville , Cape Town 7535 , South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TA  - SAHARA J
JT  - SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance
JID - 101226212
SB  - IM
MH  - Community Health Services/*organization & administration
MH  - *Community Networks/organization & administration
MH  - Evidence-Based Practice
MH  - HIV Infections/*prevention & control
MH  - Health Promotion/*organization & administration
MH  - Humans
MH  - Models, Theoretical
MH  - Organizational Innovation
MH  - Pilot Projects
MH  - South Africa/epidemiology
PMC - PMC5642432
OAB - Publisher: Abstract available from the publisher.
OABL- fre
OTO - NOTNLM
OT  - Cynefin framework
OT  - HIV/AIDS
OT  - VIH/SIDA
OT  - autopoiesis
OT  - complexity theory
OT  - futures science
OT  - sciences des futures
OT  - théorie de la complexité
EDAT- 2016/01/30 06:00
MHDA- 2016/11/05 06:00
CRDT- 2016/01/30 06:00
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2016/11/05 06:00 [medline]
AID - 1123642 [pii]
AID - 10.1080/17290376.2015.1123642 [doi]
PST - ppublish
SO  - SAHARA J. 2016;13(1):17-34. doi: 10.1080/17290376.2015.1123642.

PMID- 25707605
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20170213
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
VI  - 29
IP  - 3
DP  - 2015 May-Jun
TI  - Use of new technologies to notify possible contagion of sexually-transmitted 
      infections among men.
PG  - 190-7
LID - S0213-9111(15)00006-0 [pii]
LID - 10.1016/j.gaceta.2015.01.003 [doi]
AB  - BACKGROUND: Among men who have sex with men (MSM), the association between searching 
      for sexual partners' on the Internet and increased risk of sexually transmitted 
      infections (STIs)/HIV infection, together with current low levels of partner 
      notification (PN), justifies a study to explore the intention to use new 
      communication technologies for PN in Spain. METHODS: Two cross-sectional surveys 
      were performed: the first was administered online to visitors to web pages where the 
      survey was advertised; the second was administered on paper to patients attending an 
      STI Unit and centres similar to Community-Based Voluntary Counselling and Testing 
      centres. RESULTS: The study population comprised 1578 Spanish residents (median age, 
      34 years [range: 18 to 74]); 84% lived in urban areas, and 69% reported searching 
      for sexual partners on the Internet. Thirty-seven per cent would be willing to use a 
      website for PN, 26% did not know if they would use one, and 37% would not want to 
      use one. The main reasons for not intending to notify STI/HIV were "shame or fear" 
      (stable partner) and "not knowing how to contact them" (casual partner). The 
      preferred method of notification was face to face (73%) for both stable and casual 
      partners, although using new technologies (Short Messaging System, e-mail, web page, 
      phone applications) was widely accepted for notifying casual partners. CONCLUSIONS: 
      Fighting stigma and promoting alternative methods of PN among MSM and health 
      professionals through new technologies could increase the frequency of PN. This 
      approach will improve early detection and reduce transmission in Spain.
CI  - Copyright © 2014 SESPAS. Published by Elsevier Espana. All rights reserved.
FAU - Carnicer-Pont, Dolors
AU  - Carnicer-Pont D
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Department of Paediatrics, Obstetrics and Gynaecology of the Autonomous 
      University of Barcelona (UAB), Bellaterra, Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain. Electronic address: dcarnice@gmail.com.
FAU - Barbera-Gracia, María Jesús
AU  - Barbera-Gracia MJ
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Fernández-Dávila, Percy
AU  - Fernández-Dávila P
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Stop Sida, Barcelona, Spain.
FAU - García de Olalla, Patricia
AU  - García de Olalla P
AD  - Agència de Salut Pública de Barcelona (ASPB), Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain.
FAU - Muñoz, Rafael
AU  - Muñoz R
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Stop Sida, Barcelona, Spain.
FAU - Jacques-Aviñó, Constanza
AU  - Jacques-Aviñó C
AD  - Agència de Salut Pública de Barcelona (ASPB), Spain.
FAU - Saladié-Martí, María Pilar
AU  - Saladié-Martí MP
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Gosch-Elcoso, Mercè
AU  - Gosch-Elcoso M
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Arellano Muñoz, Encarna
AU  - Arellano Muñoz E
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Casabona, Jordi
AU  - Casabona J
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Department of Paediatrics, Obstetrics and Gynaecology of the Autonomous 
      University of Barcelona (UAB), Bellaterra, Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150221
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Community Health Centers
MH  - Contact Tracing/*methods
MH  - Cross-Sectional Studies
MH  - Emotions
MH  - Humans
MH  - *Internet
MH  - Male
MH  - Middle Aged
MH  - Sexual Behavior
MH  - *Sexual Partners
MH  - Sexually Transmitted Diseases/epidemiology/*prevention & 
      control/psychology/transmission
MH  - Social Media
MH  - Social Stigma
MH  - Socioeconomic Factors
MH  - Spain/epidemiology
MH  - Telephone
MH  - Urban Population
MH  - Young Adult
OTO - NOTNLM
OT  - Communication networks
OT  - Infección de transmisión sexual/VIH
OT  - Internet
OT  - Notificación a las parejas sexuales
OT  - Partner notification
OT  - Redes de comunicación
OT  - Sexually Transmitted Infection/HIV
EDAT- 2015/02/25 06:00
MHDA- 2017/02/14 06:00
CRDT- 2015/02/25 06:00
PHST- 2014/10/14 00:00 [received]
PHST- 2015/01/14 00:00 [revised]
PHST- 2015/01/14 00:00 [accepted]
PHST- 2015/02/25 06:00 [entrez]
PHST- 2015/02/25 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
AID - S0213-9111(15)00006-0 [pii]
AID - 10.1016/j.gaceta.2015.01.003 [doi]
PST - ppublish
SO  - Gac Sanit. 2015 May-Jun;29(3):190-7. doi: 10.1016/j.gaceta.2015.01.003. Epub 2015 
      Feb 21.

PMID- 26765073
OWN - NLM
STAT- MEDLINE
DCOM- 20161010
LR  - 20181202
IS  - 1521-0391 (Electronic)
IS  - 1055-0496 (Print)
IS  - 1055-0496 (Linking)
VI  - 25
IP  - 2
DP  - 2016 Mar
TI  - Predictors of needle exchange program utilization during its implementation and 
      expansion in Tijuana, Mexico.
PG  - 118-24
LID - 10.1111/ajad.12326 [doi]
AB  - OBJECTIVE: Until the early 2000s, there was only one needle exchange program (NEP) 
      offered in Mexico. In 2004, the second Mexican NEP opened in Tijuana, but its 
      utilization has not been studied. We studied predictors of initiating NEP during its 
      early expansion in Tijuana, Mexico. METHODS: From April 2006 to April 2007, people 
      who inject drugs (PWID) residing in Tijuana who had injected within the last month 
      were recruited using respondent-driven sampling. Weighted Poisson regression 
      incorporating generalized estimating equations was used to identify predictors of 
      initiating NEP, while accounting for correlation between recruiter and recruits. 
      RESULTS: NEP uptake increased from 20% at baseline to 59% after 6 months. Among a 
      subsample of PWID not accessing NEP at baseline (n = 480), 83% were male and median 
      age was 37 years (Interquartile Range: 32-43). At baseline, 4.4% were HIV-infected 
      and 5.9% had syphilis titers >1:8. In multivariate models, factors associated with 
      NEP initiation (p < .05) were attending shooting galleries (Adjusted Relative Risk 
      [ARR]: 1.54); arrest for track-marks (ARR: 1.38); having a family member that ever 
      used drugs (ARR: 1.37); and having a larger PWID network (ARR: 1.01 per 10 persons). 
      NEP initiation was inversely associated with obtaining syringes at pharmacies (ARR: 
      .56); earning >2500 pesos/month (ARR: .66); and reporting needle sharing (ARR: .71). 
      CONCLUSIONS: Uptake of NEP expansion in Tijuana was vigorous among PWID. We 
      identified a range of factors that influenced the likelihood of NEP initiation, 
      including police interaction. These findings have important implications for the 
      scale-up of NEP in Mexico.
CI  - © American Academy of Addiction Psychiatry.
FAU - Smith, Danielle M
AU  - Smith DM
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, 
      Canada.
FAU - Werb, Dan
AU  - Werb D
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Abramovitz, Daniela
AU  - Abramovitz D
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Magis-Rodriguez, Carlos
AU  - Magis-Rodriguez C
AD  - Centro Nacional parala Prevencion y Control del VIH/SIDA e ITS (CENSIDA), Mexico 
      City, Mexico.
FAU - Vera, Alicia
AU  - Vera A
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Patterson, Thomas L
AU  - Patterson TL
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Strathdee, Steffanie A
AU  - Strathdee SA
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
CN  - for Proyecto El Cuete
LA  - eng
GR  - DP2 DA040256-01/DA/NIDA NIH HHS/United States
GR  - R01 DA039073/DA/NIDA NIH HHS/United States
GR  - DP2 DA040256/DA/NIDA NIH HHS/United States
GR  - R01 DA019829/DA/NIDA NIH HHS/United States
GR  - R37 DA019829/DA/NIDA NIH HHS/United States
GR  - MOP-79297/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160114
TA  - Am J Addict
JT  - The American journal on addictions
JID - 9208821
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - Needle-Exchange Programs/*statistics & numerical data
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - Police/statistics & numerical data
MH  - Substance Abuse, Intravenous/*prevention & control
PMC - PMC5470727
MID - NIHMS863804
COIS- Declaration of Interest The authors report no conflicts of interest. The authors 
      alone are responsible for the content and writing of this paper
EDAT- 2016/01/15 06:00
MHDA- 2016/10/11 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/08/24 00:00 [received]
PHST- 2015/11/18 00:00 [revised]
PHST- 2015/12/10 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/10/11 06:00 [medline]
AID - 10.1111/ajad.12326 [doi]
PST - ppublish
SO  - Am J Addict. 2016 Mar;25(2):118-24. doi: 10.1111/ajad.12326. Epub 2016 Jan 14.

PMID- 30377979
OWN - NLM
STAT- MEDLINE
DCOM- 20190711
LR  - 20200225
IS  - 1573-3254 (Electronic)
IS  - 1090-7165 (Print)
IS  - 1090-7165 (Linking)
VI  - 23
IP  - 4
DP  - 2019 Apr
TI  - Making the Link: A Pilot Health Navigation Intervention to Improve Timely Linkage to 
      Care for Men Who have Sex with Men and Transgender Women Recently Diagnosed with HIV 
      in Guatemala City.
PG  - 900-907
LID - 10.1007/s10461-018-2328-6 [doi]
AB  - We piloted a health navigation strategy to promote timely linkage to care among men 
      who have sex with men (MSM) and transgender women (TW) recently diagnosed with HIV 
      in Guatemala City. We used a mixed-methods approach, integrating quantitative data 
      collected during clinic visits and qualitative data from in-depth interviews, to 
      characterize acceptability of navigation and time to linkage, defined as having the 
      first clinical care visit. Out of 54 participants who enrolled in the pilot (n = 52 
      MSM; n = 2 TW), 50 (92.6%) accepted navigation and all were linked to care. Median 
      time to linkage was 3 days (Interquartile Range 2-5 days). In qualitative 
      interviews, participants expressed feeling scared and alone following their 
      diagnosis and appreciated the support of a navigator, especially when they did not 
      feel they could access their existing support networks. Future research and 
      evaluation should continue to assess how to best use health navigation to support 
      key populations recently diagnosed with HIV.
FAU - Loya-Montiel, M Itzel
AU  - Loya-Montiel MI
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Davis, Dirk A
AU  - Davis DA
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, USA.
FAU - Aguilar-Martínez, Jose Manuel
AU  - Aguilar-Martínez JM
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Paz Bailey, Olga Alicia
AU  - Paz Bailey OA
AD  - Center for Conflict, Power and Violence Studies - CENDES, Guatemala City, Guatemala.
FAU - Morales-Miranda, Sonia
AU  - Morales-Miranda S
AD  - Consorcio de Investigación sobre VIH, SIDA y TB (CISIDAT), Cuernavaca, Mexico.
FAU - Alvis-Estrada, Juan Pablo
AU  - Alvis-Estrada JP
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Northbrook, Sanny
AU  - Northbrook S
AD  - U.S. Centers for Disease Control and Prevention (CDC) Central America Region, 
      Guatemala City, Guatemala.
FAU - Barrington, Clare
AU  - Barrington C
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, USA. cbarring@email.unc.edu.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
GR  - GH0000575/U.S. President's Emergency Plan for AIDS Relief/
PT  - Journal Article
TA  - AIDS Behav
JT  - AIDS and behavior
JID - 9712133
SB  - IM
MH  - Adult
MH  - *Continuity of Patient Care
MH  - Female
MH  - Guatemala/epidemiology
MH  - HIV Infections/diagnosis/*drug therapy/epidemiology
MH  - *Health Services Accessibility/statistics & numerical data
MH  - Homosexuality, Male/*psychology
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - *Patient Navigation
MH  - Pilot Projects
MH  - Qualitative Research
MH  - Sexual and Gender Minorities
MH  - Transgender Persons/psychology
MH  - Transsexualism/*psychology
PMC - PMC6691504
MID - NIHMS1045779
OTO - NOTNLM
OT  - Guatemala
OT  - HIV
OT  - Health navigation
OT  - Linkage to care
OT  - MSM
COIS- Disclosure Statement: No potential conflict of interest was reported by the authors.
EDAT- 2018/11/01 06:00
MHDA- 2019/07/12 06:00
CRDT- 2018/11/01 06:00
PHST- 2018/11/01 06:00 [pubmed]
PHST- 2019/07/12 06:00 [medline]
PHST- 2018/11/01 06:00 [entrez]
AID - 10.1007/s10461-018-2328-6 [pii]
AID - 10.1007/s10461-018-2328-6 [doi]
PST - ppublish
SO  - AIDS Behav. 2019 Apr;23(4):900-907. doi: 10.1007/s10461-018-2328-6.

PMID- 26482266
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20170916
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Linking)
VI  - 22
IP  - 2
DP  - 2016 Feb
TI  - Contribution of APOBEC3G/F activity to the development of low-abundance 
      drug-resistant human immunodeficiency virus type 1 variants.
PG  - 191-200
LID - S1198-743X(15)00903-9 [pii]
LID - 10.1016/j.cmi.2015.10.004 [doi]
AB  - Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) 
      increase the risk of virological failure to first-line non-nucleoside reverse 
      transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in 
      ART-naive patients, however, remains unclear. In a large pan-European case-control 
      study investigating the clinical relevance of pre-existing DRMVs using 454 
      pyrosequencing, the six most prevalent plasma DRMVs detected corresponded to G-to-A 
      nucleotide mutations (V90I, V106I, V108I, E138K, M184I and M230I). Here, we 
      evaluated if such DRMVs could have emerged from apolipoprotein B mRNA editing 
      enzyme, catalytic polypeptide 3G/F (APOBEC3G/F) activity. Out of 236 ART-naive 
      subjects evaluated, APOBEC3G/F hypermutation signatures were detected in plasma 
      viruses of 14 (5.9%) individuals. Samples with minority E138K, M184I, and M230I 
      mutations, but not those with V90I, V106I or V108I, were significantly associated 
      with APOBEC3G/F activity (Fisher's P < 0.005), defined as the presence of > 0.5% of 
      sample sequences with an APOBEC3G/F signature. Mutations E138K, M184I and M230I 
      co-occurred in the same sequence as APOBEC3G/F signatures in 3/9 (33%), 5/11 (45%) 
      and 4/8 (50%) of samples, respectively; such linkage was not found for V90I, V106I 
      or V108I. In-frame STOP codons were observed in 1.5% of all clonal sequences; 14.8% 
      of them co-occurred with APOBEC3G/F signatures. APOBEC3G/F-associated E138K, M184I 
      and M230I appeared within clonal sequences containing in-frame STOP codons in 2/3 
      (66%), 5/5 (100%) and 4/4 (100%) of the samples. In a re-analysis of the parent case 
      control study, the presence of APOBEC3G/F signatures was not associated with 
      virological failure. In conclusion, the contribution of APOBEC3G/F editing to the 
      development of DRMVs is very limited and does not affect the efficacy of 
      non-nucleoside reverse transcriptase inhibitor ART.
CI  - Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Noguera-Julian, M
AU  - Noguera-Julian M
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain. Electronic address: 
      mnoguera@irsicaixa.es.
FAU - Cozzi-Lepri, A
AU  - Cozzi-Lepri A
AD  - University College London, London, UK.
FAU - Di Giallonardo, F
AU  - Di Giallonardo F
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Schuurman, R
AU  - Schuurman R
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Däumer, M
AU  - Däumer M
AD  - Institut für Immunologie und Genetik, Kaiserslautern, Germany.
FAU - Aitken, S
AU  - Aitken S
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Ceccherini-Silberstein, F
AU  - Ceccherini-Silberstein F
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - D'Arminio Monforte, A
AU  - D'Arminio Monforte A
AD  - Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, 
      University of Milan, Milan, Italy.
FAU - Geretti, A M
AU  - Geretti AM
AD  - Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
FAU - Booth, C L
AU  - Booth CL
AD  - Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
FAU - Kaiser, R
AU  - Kaiser R
AD  - Institute of Virology, University of Cologne, Cologne, Germany.
FAU - Michalik, C
AU  - Michalik C
AD  - Competence Network for HIV/AIDS, Bochum, Germany; Clinic for Dermatology, 
      Venereology and Allergology of the Ruhr-Universität, Bochum, Germany; Clinical Trial 
      Centre (ZKS), University Cologne, Germany.
FAU - Jansen, K
AU  - Jansen K
AD  - Competence Network for HIV/AIDS, Bochum, Germany; Clinic for Dermatology, 
      Venereology and Allergology of the Ruhr-Universität, Bochum, Germany.
FAU - Masquelier, B
AU  - Masquelier B
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, 
      Bordeaux, France.
FAU - Bellecave, P
AU  - Bellecave P
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, 
      Bordeaux, France.
FAU - Kouyos, R D
AU  - Kouyos RD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Castro, E
AU  - Castro E
AD  - Addiction Medicine, Service of Community Psychiatry, Centre Hospitalier 
      Universitaire Vaudois, Lausanne, Switzerland.
FAU - Furrer, H
AU  - Furrer H
AD  - Department of Infectious Diseases, Bern University Hospital and University of Bern, 
      Bern, Switzerland.
FAU - Schultze, A
AU  - Schultze A
AD  - University College London, London, UK.
FAU - Günthard, H F
AU  - Günthard HF
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, 
      University of Zurich, Zurich, Switzerland.
FAU - Brun-Vezinet, F
AU  - Brun-Vezinet F
AD  - Department of Virology, Bichat University Hospital, Paris7, France.
FAU - Metzner, K J
AU  - Metzner KJ
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, 
      University of Zurich, Zurich, Switzerland.
FAU - Paredes, R
AU  - Paredes R
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
CN  - CHAIN Minority HIV-1 Variants Working group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151023
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European 
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
RN  - 0 (RNA, Viral)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - EC 3.5.4.1 (APOBEC3F protein, human)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
RN  - EC 3.5.4.5 (APOBEC-3G Deaminase)
RN  - EC 3.5.4.5 (APOBEC3G protein, human)
RN  - EC 3.5.4.5 (Cytidine Deaminase)
SB  - IM
MH  - APOBEC-3G Deaminase
MH  - Antiretroviral Therapy, Highly Active
MH  - Case-Control Studies
MH  - Cytidine Deaminase/*genetics
MH  - Cytosine Deaminase/*genetics
MH  - *Drug Resistance, Viral
MH  - Female
MH  - HIV Infections/drug therapy/metabolism/*virology
MH  - HIV-1/*genetics
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - RNA Editing
MH  - RNA, Viral/genetics/metabolism
MH  - Reverse Transcriptase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - APOBEC3
OT  - NNRTI resistance
OT  - human immunodeficiency virus type 1
OT  - minority variants
OT  - resistance
FIR - Paredes, Roger
IR  - Paredes R
FIR - Metzner, Karin J
IR  - Metzner KJ
FIR - Cozzi-Lepri, Alessandro
IR  - Cozzi-Lepri A
FIR - Schuurman, Rob
IR  - Schuurman R
FIR - Brun-Vezinet, Francoise
IR  - Brun-Vezinet F
FIR - Günthard, Huldrych
IR  - Günthard H
FIR - Ceccherini-Silberstein, Francesca
IR  - Ceccherini-Silberstein F
FIR - Kaiser, Rolf
IR  - Kaiser R
FIR - Geretti, Anna Maria
IR  - Geretti AM
FIR - Brockmeyer, Norbert
IR  - Brockmeyer N
FIR - Masquelier, Bernard
IR  - Masquelier B
EDAT- 2015/10/21 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/05/13 00:00 [received]
PHST- 2015/09/07 00:00 [revised]
PHST- 2015/10/03 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - S1198-743X(15)00903-9 [pii]
AID - 10.1016/j.cmi.2015.10.004 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004. Epub 
      2015 Oct 23.

PMID- 30722780
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200309
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Feb 5
TI  - High level of treatment failure and drug resistance to first-line antiretroviral 
      therapies among HIV-infected children receiving decentralized care in Senegal.
PG  - 47
LID - 10.1186/s12887-019-1420-z [doi]
LID - 47
AB  - BACKGROUND: In Senegal in 2015, an estimated 4800 children were living with HIV, 
      with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized 
      sites outside Dakar. However, until now no studies have determined the efficacy of 
      pediatric treatment in decentralized settings, even though the emergence of viral 
      resistance, particularly among children in Africa, is a well-known phenomenon. This 
      study aimed to assess the virological status of HIV-infected children in all 
      decentralized facilities to help improve access to quality care. METHODS: A 
      cross-sectional epidemiological and virological study was conducted in all of 
      Senegal's regions, except Dakar, between March and June 2015 and sought to include 
      all HIV-infected children and adolescents (0-19 years), treated or not with ARVs. 
      Socio-demographic and clinical data and a blood sample on blotting paper were 
      collected for children from treatment sites. Samples were routed on public 
      transportation, assisted by a network of community health workers. A viral load (VL) 
      assay was performed for each child, followed by genotyping when it exceeded 1000 
      copies/mL (3 log(10)). RESULTS: Of the 851 identified children, 666 (78%) were 
      enrolled in the study. Half of the children were girls, and the average age was 
      8 years (6 months-19 years). Most of the children (96.7%) were infected with HIV-1, 
      and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic 
      regimen. The median duration of time on ART was 21 months (1-129). VL was measured 
      for 2% of children before this study. Almost two-thirds (64%) of the children are 
      experiencing virological failure. Among them, there was resistance to at least one 
      drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% 
      to two out of three. For nearly one-third of the children presenting resistance, 
      none of the three drugs of the treatment was active. Factors associated with 
      virological failure were male sex, follow-up by a generalist rather than a 
      specialist, and treatment interruptions. CONCLUSIONS: We observed a high level of 
      virological failure and a high percentage of viral resistance among children 
      receiving health care in decentralized facilities in Senegal.
FAU - Cissé, Abdoul-Magib
AU  - Cissé AM
AD  - Service de pédiatrie Établissement Public de Santé (EPS) de Mbour, UFR Sciences de 
      la Santé, Thiès University, Thiès, Senegal.
FAU - Laborde-Balen, Gabrièle
AU  - Laborde-Balen G
AD  - Expertise France, Paris, France.
AD  - ANRS-Senegal site, Dakar, Senegal.
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
FAU - Kébé-Fall, Khady
AU  - Kébé-Fall K
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Dramé, Aboubacry
AU  - Dramé A
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Diop, Halimatou
AU  - Diop H
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Diop, Karim
AU  - Diop K
AD  - Expertise France, Paris, France.
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - FatouNiasse-Traoré
AU  - FatouNiasse-Traoré
AD  - Conseil national de lutte contre le sida (CNLS), Dakar, Senegal.
FAU - Coulibaly, Mohamed
AU  - Coulibaly M
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - Have, Ndeye-Ngone
AU  - Have NN
AD  - Réseau national des associations de personnes vivant avec le VIH au (RNP+), Dakar, 
      Senegal.
FAU - Vidal, Nicole
AU  - Vidal N
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Thiam, Safiatou
AU  - Thiam S
AD  - Conseil national de lutte contre le sida (CNLS), Dakar, Senegal.
FAU - Wade, Abdoulaye S
AU  - Wade AS
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - Peeters, Martine
AU  - Peeters M
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Taverne, Bernard
AU  - Taverne B
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Msellati, Philippe
AU  - Msellati P
AUID- ORCID: 0000-0003-2568-1626
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France. 
      philippe.msellati@ird.fr.
AD  - TransVIHMI, IRD, PACCI, 18 BP 1954, Abidjan 18, Abidjan, Côte d'Ivoire. 
      philippe.msellati@ird.fr.
FAU - Touré-Kane, Coumba
AU  - Touré-Kane C
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190205
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Adolescent
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/organization & administration
MH  - *Drug Resistance, Viral
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Senegal/epidemiology
MH  - *Treatment Failure
MH  - Young Adult
PMC - PMC6362577
OTO - NOTNLM
OT  - *Antiretroviral
OT  - *Decentralization
OT  - *Pediatric HIV
OT  - *Senegal
OT  - *Viral resistance
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The protocol was approved by the 
      National Ethics Committee for Research in Health in Senegal on 16 December 2014 
      under no. 377/MSAS/DPRS/CNERS. All parents or guardians provided written informed 
      consent. CONSENT FOR PUBLICATION: “Not applicable”. COMPETING INTERESTS: The authors 
      declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature 
      remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2019/02/07 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/02/07 06:00
PHST- 2018/10/12 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/02/07 06:00 [entrez]
PHST- 2019/02/07 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
AID - 10.1186/s12887-019-1420-z [pii]
AID - 1420 [pii]
AID - 10.1186/s12887-019-1420-z [doi]
PST - epublish
SO  - BMC Pediatr. 2019 Feb 5;19(1):47. doi: 10.1186/s12887-019-1420-z.

PMID- 25336166
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20211021
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Print)
IS  - 0305-7453 (Linking)
VI  - 70
IP  - 3
DP  - 2015 Mar
TI  - Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line 
      NNRTI-based ART: a multicohort European case-control study using centralized 
      ultrasensitive 454 pyrosequencing.
PG  - 930-40
LID - 10.1093/jac/dku426 [doi]
AB  - OBJECTIVES: It is still debated if pre-existing minority drug-resistant HIV-1 
      variants (MVs) affect the virological outcomes of first-line NNRTI-containing ART. 
      METHODS: This Europe-wide case-control study included ART-naive subjects infected 
      with drug-susceptible HIV-1 as revealed by population sequencing, who achieved 
      virological suppression on first-line ART including one NNRTI. Cases experienced 
      virological failure and controls were subjects from the same cohort whose viraemia 
      remained suppressed at a matched time since initiation of ART. Blinded, centralized 
      454 pyrosequencing with parallel bioinformatic analysis in two laboratories was used 
      to identify MVs in the 1%-25% frequency range. ORs of virological failure according 
      to MV detection were estimated by logistic regression. RESULTS: Two hundred and 
      sixty samples (76 cases and 184 controls), mostly subtype B (73.5%), were used for 
      the analysis. Identical MVs were detected in the two laboratories. 31.6% of cases 
      and 16.8% of controls harboured pre-existing MVs. Detection of at least one MV 
      versus no MVs was associated with an increased risk of virological failure 
      (OR = 2.75, 95% CI = 1.35-5.60, P = 0.005); similar associations were observed for 
      at least one MV versus no NRTI MVs (OR = 2.27, 95% CI = 0.76-6.77, P = 0.140) and at 
      least one MV versus no NNRTI MVs (OR = 2.41, 95% CI = 1.12-5.18, P = 0.024). A 
      dose-effect relationship between virological failure and mutational load was found. 
      CONCLUSIONS: Pre-existing MVs more than double the risk of virological failure to 
      first-line NNRTI-based ART.
CI  - © The Author 2014. Published by Oxford University Press on behalf of the British 
      Society for Antimicrobial Chemotherapy.
FAU - Cozzi-Lepri, Alessandro
AU  - Cozzi-Lepri A
AD  - University College London, London, UK.
FAU - Noguera-Julian, Marc
AU  - Noguera-Julian M
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
FAU - Di Giallonardo, Francesca
AU  - Di Giallonardo F
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Schuurman, Rob
AU  - Schuurman R
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Däumer, Martin
AU  - Däumer M
AD  - Institut für Immunologie und Genetik, Kaiserslautern, Germany.
FAU - Aitken, Sue
AU  - Aitken S
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Ceccherini-Silberstein, Francesca
AU  - Ceccherini-Silberstein F
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - D'Arminio Monforte, Antonella
AU  - D'Arminio Monforte A
AD  - Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, 
      University of Milan, Milan, Italy.
FAU - Geretti, Anna Maria
AU  - Geretti AM
AD  - Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
FAU - Booth, Clare L
AU  - Booth CL
AD  - Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
FAU - Kaiser, Rolf
AU  - Kaiser R
AD  - Institute of Virology, University of Cologne, Cologne, Germany.
FAU - Michalik, Claudia
AU  - Michalik C
AD  - Competence Network for HIV/AIDS, Bochum, Germany and Clinic for Dermatology, 
      Venerology and Allergology of the Ruhr-Universität, Bochum, Germany Clinical Trial 
      Centre (ZKS), University of Cologne, Cologne, Germany.
FAU - Jansen, Klaus
AU  - Jansen K
AD  - Competence Network for HIV/AIDS, Bochum, Germany and Clinic for Dermatology, 
      Venerology and Allergology of the Ruhr-Universität, Bochum, Germany.
FAU - Masquelier, Bernard
AU  - Masquelier B
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Université Bordeaux 2, 
      Bordeaux, France.
FAU - Bellecave, Pantxika
AU  - Bellecave P
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Université Bordeaux 2, 
      Bordeaux, France.
FAU - Kouyos, Roger D
AU  - Kouyos RD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Castro, Erika
AU  - Castro E
AD  - Addiction Medicine, Service of Community Psychiatry, Centre Hospitalier 
      Universitaire Vaudois, Lausanne, Switzerland.
FAU - Furrer, Hansjakob
AU  - Furrer H
AD  - Department of Infectious Diseases, Bern University Hospital and University of Bern, 
      Bern, Switzerland.
FAU - Schultze, Anna
AU  - Schultze A
AD  - University College London, London, UK.
FAU - Günthard, Huldrych F
AU  - Günthard HF
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Brun-Vezinet, Francoise
AU  - Brun-Vezinet F
AD  - Department of Virology, Bichat University Hospital, Paris, France.
FAU - Paredes, Roger
AU  - Paredes R
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
FAU - Metzner, Karin J
AU  - Metzner KJ
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland karin.metzner@usz.ch.
CN  - CHAIN Minority HIV-1 Variants Working Group
LA  - eng
PT  - Journal Article
DEP - 20141021
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Reverse Transcriptase Inhibitors)
SB  - IM
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Computational Biology
MH  - *Drug Resistance, Viral
MH  - Europe
MH  - Female
MH  - Genotype
MH  - HIV Infections/*drug therapy/*virology
MH  - HIV-1/*drug effects/genetics/isolation & purification
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Male
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
MH  - Risk Assessment
MH  - Sequence Analysis, DNA
MH  - Treatment Failure
MH  - Young Adult
PMC - PMC4319483
OTO - NOTNLM
OT  - CHAIN
OT  - European multicentre study
OT  - antiretroviral therapy
OT  - minority drug-resistant HIV-1 variants
FIR - Paredes, Roger
IR  - Paredes R
FIR - Metzner, Karin J
IR  - Metzner KJ
FIR - Cozzi-Lepri, Alessandro
IR  - Cozzi-Lepri A
FIR - Schuurman, Rob
IR  - Schuurman R
FIR - Brun-Vezinet, Francoise
IR  - Brun-Vezinet F
FIR - Günthard, Huldrych
IR  - Günthard H
FIR - Ceccherini-Silberstein, Francesca
IR  - Ceccherini-Silberstein F
FIR - Kaiser, Rolf
IR  - Kaiser R
FIR - Geretti, Anna Maria
IR  - Geretti AM
FIR - Brockmeyer, Norbert
IR  - Brockmeyer N
FIR - Masquelier, Bernard
IR  - Masquelier B
EDAT- 2014/10/23 06:00
MHDA- 2015/10/17 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/10/23 06:00 [entrez]
PHST- 2014/10/23 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
AID - dku426 [pii]
AID - 10.1093/jac/dku426 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 
      Oct 21.
